Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast 25 June
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis 22 June
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO 04 June
